<DOC>
	<DOCNO>NCT02211131</DOCNO>
	<brief_summary>This phase 2 , multicenter , randomize , open-label study estimate efficacy talimogene laherparepvec neoadjuvant treatment follow surgery compare surgery alone subject completely resectable stage IIIB , IIIC , IVM1a melanoma .</brief_summary>
	<brief_title>Efficacy Safety Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone Melanoma</brief_title>
	<detailed_description>This phase 2 , multicenter , randomize , open-label study estimate efficacy talimogene laherparepvec neoadjuvant treatment follow surgery compare surgery alone subject completely resectable stage IIIB , IIIC , IVM1a melanoma . Arm 1 : Talimogene laherparepvec 6 dos follow surgical resection melanoma tumor lesion ( ) . Arm 2 : Immediate surgical resection melanoma tumor lesion ( ) Following surgery , adjuvant systemic therapy and/or radiotherapy may administer investigator 's discretion per institutional standard care . Subjects follow safety approximately 30 ( +15 ) day surgery disease recurrence , subsequent anticancer therapy , survival every 3 month ( ±30 day ) first 3 year end safety follow-up period every 6 month ( ±30 day ) death , subject withdraws full consent , 5 year last subject randomize .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm diagnosis stage IIIB , IIIC IVM1a melanoma eligible complete surgical resection . Prior systemic , regional radiation anticancer therapy melanoma must complete least 3 month prior randomization . Subject must measurable disease must candidate intralesional therapy least one injectable cutaneous , subcutaneous , nodal melanoma lesion ( ≥ 10 mm long diameter ) multiple injectable lesion aggregate long diameter ≥ 10 mm . Subject must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 must serum lactate dehydrogenase ( LDH ) ≤ 1.0 X upper limit normal adequate hematologic , hepatic , renal , coagulation organ function Other criterion may apply Subject must primary ocular mucosal melanoma , history evidence melanoma associate immunodeficiency state ( eg , hereditary immune deficiency , organ transplant , leukemia ) . Subject must history evidence symptomatic autoimmune pneumonitis , glomerulonephritis , vasculitis , symptomatic autoimmune disease . Subject must evidence clinically significant immunosuppression active herpetic skin lesion prior complication herpes simplex type 1 ( HSV1 ) infection ( eg , herpetic keratitis encephalitis ) must require intermittent chronic systemic treatment antiherpetic drug ( eg , acyclovir ) , intermittent topical use . Subject know acute chronic active hepatitis B , hepatitis C , human immunodeficiency virus infection also exclude . Subject must treat previously talimogene laherparepvec tumor vaccine . Other criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>